RTI Surgical (RTIX) 10-Q 7 Nov 13 2013 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Sep. 30, 2013	Nov. 01, 2013
Document And Entity Information [Abstract]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Sep-13	'
Document Fiscal Year Focus	'2013	'
Document Fiscal Period Focus	'Q3	'
Entity Registrant Name	'RTI SURGICAL, INC.	'
Entity Central Index Key	'0001100441	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	56,387,263

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Current Assets:	'	'
Cash and cash equivalents	$16,135	$49,696
Accounts receivable - less allowances of $436 at September 30, 2013 and $346 at December 31, 2012	33,294	21,694
Inventories - net	113,138	76,509
Prepaid and other current assets	7,833	6,075
Deferred tax assets - net	17,584	12,598
Total current assets	187,984	166,572
Property, plant and equipment - net	72,818	49,644
Deferred tax assets - net	8,307	8,652
Goodwill	55,277	2,062
Other intangible assets - net	35,444	13,766
Other assets - net	14,276	713
Total assets	374,106	241,409
Current Liabilities:	'	'
Accounts payable	23,505	11,949
Accrued expenses	19,563	20,594
Current portion of deferred revenue	5,034	4,803
Current portion of long-term obligations	28	116
Total current liabilities	48,130	37,462
Long-term obligations - less current portion	68,382	4
Other long-term liabilities	14,626	698
Deferred tax liabilities	939	473
Deferred revenue	17,052	18,780
Total liabilities	149,129	57,417
Preferred stock Series A, $.001 par value: 5,000,000 shares authorized; 50,000 shares issued and outstanding at September 30, 2013	49,381	'
Stockholders' equity:	'	'
Common stock, $.001 par value: 150,000,000 shares authorized; 56,387,263 and 55,985,394 shares issued and outstanding, respectively	56	56
Additional paid-in capital	415,674	414,482
Accumulated other comprehensive loss	-1,294	-1,776
Accumulated deficit	-238,773	-228,736
Less treasury stock, 146,957 and 138,297 shares, at cost	-67	-34
Total stockholders' equity	175,596	183,992
Total liabilities and stockholders' equity	$374,106	$241,409

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, except Share data, unless otherwise specified
Statement Of Financial Position [Abstract]	'	'
Accounts receivable, allowances	$436	$346
Preferred stock, par value	$0.00	'
Preferred stock, shares authorized	5,000,000	'
Preferred stock, shares issued	50,000	'
Preferred stock, shares outstanding	50,000	'
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	150,000,000	150,000,000
Common stock, shares issued	56,387,263	56,387,263
Common stock, shares outstanding	55,985,394	55,985,394
Treasury stock, shares	146,957	138,297

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Comprehensive (Loss) Income (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Income Statement [Abstract]	'	'	'	'
Revenues	$54,742	$44,566	$137,473	$133,506
Costs of processing and distribution	34,423	22,874	78,722	70,037
Gross profit	20,319	21,692	58,751	63,469
Expenses:	'	'	'	'
Marketing, general and administrative	24,837	14,499	55,555	43,167
Research and development	4,738	3,109	11,190	9,279
Asset abandonments	'	'	'	18
Litigation settlement	'	'	3,000	2,350
Acquisition expenses	4,342	'	5,837	'
Total operating expenses	33,917	17,608	75,582	54,814
Operating (loss) income	-13,598	4,084	-16,831	8,655
Other income (expense):	'	'	'	'
Interest expense	-262	'	-262	'
Interest income	14	27	23	118
Foreign exchange gain	252	5	246	20
Total other income - net	4	32	7	138
(Loss) income before income tax benefit (provision)	-13,594	4,116	-16,824	8,793
Income tax benefit (provision)	5,094	-1,308	6,787	-2,662
Net (loss) income	-8,500	2,808	-10,037	6,131
Convertible preferred dividend	-625	'	-625	'
Net (loss) income applicable to common shares	-9,125	2,808	-10,662	6,131
Other comprehensive (loss) income:	'	'	'	'
Unrealized foreign currency translation gain (loss)	797	449	482	-160
Comprehensive (loss) income	($8,328)	$3,257	($10,180)	$5,971
Net (loss) income per common share - basic	($0.16)	$0.05	($0.19)	$0.11
Net (loss) income per common share - diluted	($0.16)	$0.05	($0.19)	$0.11
Weighted average shares outstanding - basic	56,356,885	55,908,574	56,216,200	55,826,306
Weighted average shares outstanding - diluted	56,356,885	56,110,898	56,216,200	56,013,541

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Cash Flows (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Cash flows from operating activities:	'	'	'	'
Net (loss) income	($8,500)	$2,808	($10,037)	$6,131
Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities:	'	'	'	'
Depreciation and amortization expense	4,091	2,035	8,214	5,914
Provision for bad debts and product returns	132	5	295	121
Provision for inventory write-downs	552	617	1,898	3,100
Amortization of deferred revenue	-1,182	-1,163	-5,229	-3,491
Deferred income tax (benefit) provision	-5,856	1,573	-7,782	1,043
Stock-based compensation	584	524	1,653	1,574
Other	-2,757	-2,290	472	98
Change in assets and liabilities:	'	'	'	'
Accounts receivable	-883	1,899	-1,321	-209
Inventories	2,017	457	-2,293	1,116
Accounts payable	3,631	1,118	5,262	197
Accrued expenses	1,561	1,760	-5,194	288
Deferred revenue	'	'	3,000	3,000
Other operating assets and liabilities	-476	-1,224	-808	-1,583
Net cash (used in) provided by operating activities	-7,086	8,119	-11,870	17,299
Cash flows from investing activities:	'	'	'	'
Purchases of property, plant and equipment	-6,282	-2,235	-11,154	-6,844
Acquired intangible asset costs	-342	-1,015	-576	-1,391
Acquisition of Pioneer Surgical Technology	-126,307	'	-126,307	'
Other investing activities	'	49	'	49
Net cash used in investing activities	-132,931	-3,201	-138,037	-8,186
Cash flows from financing activities:	'	'	'	'
Proceeds from exercise of common stock options	117	176	330	390
Proceeds from long-term obligations	68,250	'	68,250	'
Payment of debt issuance costs	-582	'	-582	'
Proceeds from preferred stock issuance	50,000	'	50,000	'
Payment of preferred stock issuance costs	-1,290	'	-1,290	'
Payments on long-term obligations	-28	-95	-121	-389
Other financing activities	-19	'	-538	-20
Net cash provided by (used in) financing activities	116,448	81	116,049	-19
Effect of exchange rate changes on cash and cash equivalents	311	12	297	-30
Net (decrease) increase in cash and cash equivalents	-23,258	5,011	-33,561	9,064
Cash and cash equivalents, beginning of period	39,393	50,231	49,696	46,178
Cash and cash equivalents, end of period	$16,135	$55,242	$16,135	$55,242

Condensed_Consolidated_Stateme2

Condensed Consolidated Statement of Stockholders' Equity (USD $)	Total	Series A Preferred Stock [Member]	Common Stock [Member]	Additional Paid-In Capital [Member]	Additional Paid-In Capital [Member]	Accumulated Other Comprehensive Loss [Member]	Accumulated Deficit [Member]	Treasury Stock [Member]
In Thousands					Series A Preferred Stock [Member]
Beginning Balance at Dec. 31, 2012	$183,992	'	$56	$414,482	'	($1,776)	($228,736)	($34)
Net loss	-10,037	'	'	'	'	'	-10,037	'
Foreign currency translation adjustment	482	'	'	'	'	482	'	'
Exercise of common stock options	330	'	'	330	'	'	'	'
Stock-based compensation	1,653	'	'	1,653	'	'	'	'
Purchase of treasury stock	-33	'	'	'	'	'	'	-33
Amortization of preferred stock Series A issuance costs	-46	-46	'	'	-46	'	'	'
Preferred stock Series A dividend	'	-625	'	'	-625	'	'	'
Change in tax benefit from stock-based compensation	-120	'	'	-120	'	'	'	'
Ending Balance at Sep. 30, 2013	$175,596	'	$56	$415,674	'	($1,294)	($238,773)	($67)

Operations_and_Organization

Operations and Organization	9 Months Ended
	Sep. 30, 2013
Accounting Policies [Abstract]	'
Operations and Organization	'
	1	Operations and Organization
	The Company is a leader in the use of natural tissues, metals and synthetics to produce orthopedic and other surgical implants that repair and promote the natural healing of human bone and other human tissues and improve surgical outcomes. The Company processes donated human musculoskeletal and other tissue, including bone, cartilage, tendon, ligament, fascia lata, pericardium, sclera and dermal tissue, and bovine animal tissue in producing allograft and xenograft implants utilizing our proprietary BIOCLEANSE® and TUTOPLAST® sterilization processes, for distribution to hospitals and surgeons. As of September 30, 2013, the Company processes natural tissues at two facilities in Alachua, Florida and one facility in Neunkirchen, Germany, and manufactures metal and synthetic products in Marquette, Michigan and Greenville, North Carolina. The Company distributes its implants and products in all 50 states and in over 45 countries worldwide.
	As explained further in Note 4, on June 12, 2013, the Company entered into a merger agreement in connection with the acquisition of Pioneer Surgical Technology, Inc. (“Pioneer”) and in July 2013, we completed the acquisition of Pioneer. Pioneer was formerly a manufacturer of metal and synthetic products in the orthopedics, biologics, spine, trauma and cardiothoracic markets. Pioneer’s corporate headquarters were located in Marquette, Michigan with international headquarters in Houten, The Netherlands.
	On July16, 2013, the Company changed its name from RTI Biologics, Inc. to RTI Surgical, Inc.

Basis_of_Presentation

Basis of Presentation	9 Months Ended
	Sep. 30, 2013
Accounting Policies [Abstract]	'
Basis of Presentation	'
	2	Basis of Presentation
	The accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring accruals, which the Company considers necessary for a fair presentation of the results of operations for the periods shown. The condensed consolidated financial statements have been prepared in accordance with the instructions to Form 10-Q and, therefore, do not include all information and footnotes necessary for a fair presentation of consolidated financial position, results of operations and cash flows in conformity with accounting principles generally accepted in the United States of America. All intercompany balances and transactions have been eliminated in consolidation. The results of operations for any interim period are not necessarily indicative of the results to be expected for the full year. For further information, refer to the consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2012.
	The condensed consolidated financial statements include the accounts of RTI Surgical, Inc. and its wholly owned subsidiaries as of September 30, 2013, Pioneer, Tutogen Medical, Inc. (“TMI”), RTI Surgical, Inc. – Cardiovascular (inactive), Biological Recovery Group, Inc. (inactive), and RTI Services, Inc. (inactive). The condensed consolidated financial statements also include the accounts of RTI Donor Services, Inc. (“RTIDS”), which is a controlled entity. The condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2013
Accounting Policies [Abstract]	'
Summary of Significant Accounting Policies	'
	3	Summary of Significant Accounting Policies
	Cash and Cash Equivalents—The Company considers all funds in banks and short-term highly liquid investments with an original maturity of three months or less to be cash and cash equivalents. Cash equivalents comprise overnight repurchase agreements. Cash balances are held at a few financial institutions and usually exceed insurable amounts. The Company mitigates this risk by depositing its uninsured cash in major well capitalized financial institutions, and by investing excess operating cash in overnight repurchase agreements which are 101% collateralized by U.S. Government backed securities with the Company’s bank. At September 30, 2013, the Company had no cash equivalents as the full balance of cash and cash equivalents was held as cash. At December 31, 2012, the Company had $6,667 of overnight repurchase agreements in cash equivalents, which represent less than 3% and 4% of the Company’s total assets and equity, respectively.

Merger_with_Pioneer_Surgical_T

Merger with Pioneer Surgical Technology, Inc.	9 Months Ended
	Sep. 30, 2013
Business Combinations [Abstract]	'
Merger with Pioneer Surgical Technology, Inc.	'
	4	Merger with Pioneer Surgical Technology, Inc.
	On July 16, 2013, the Company completed its acquisition of Pioneer. Under the terms of the merger agreement dated June 12, 2013, the Company acquired Pioneer for $126,307 in cash. The transaction was funded through a combination of cash on hand, a new credit facility and a concurrent private placement of convertible preferred equity. The Company obtained from Toronto-Dominion Bank, N.A., TD Securities “USA” LLC (“TD Bank”) and Regions Bank, a 5 year, $80,000 senior secured facility, which includes a $60,000 term loan and a $20,000 revolving credit facility, that matures on July 16, 2018 with a variable interest rate between 100 and 175 basis points in excess of the one month LIBOR rate. The $20,000 revolving credit facility replaced the Company’s previous $15,000 U.S. credit facility.
	Additionally, the Company received $50,000 in gross proceeds from a private placement of convertible preferred equity to WSHP Biologics Holdings, LLC, (“WSHP”), a leading healthcare-focused private equity firm. The convertible preferred stock will be convertible into shares of the Company’s common stock, subject to the satisfaction of certain conditions. The convertible preferred stock will also accrue dividends at a rate of 6% per year, subject to adjustment under specified conditions. In the third quarter of 2013, the Company capitalized $1,872 in financing costs associated with the preferred stock issuance and the debt issuance. The Company expensed $4,342 and $5,837 million of acquisition costs in the three and nine months ended September 30, 2013, respectively. The acquisition costs are reflected separately in the accompanying Condensed Consolidated Statements of Comprehensive (Loss) Income.
	The Company has accounted for the acquisition of Pioneer under Accounting Standards Codification (“ASC”) 805, Business Combinations. Pioneer’s results of operations are included in the consolidated financial statements for periods ending after July 16, 2013, the acquisition date.
	The preliminary purchase price was financed as follows:
			(In thousands)
	Cash proceeds from term loan		$	60,000
	Net cash proceeds from preferred share issuance			48,710
	Cash from RTI Surgical			17,597
	Total purchase price		$	126,307
	The table below represents a preliminary allocation of the total consideration to Pioneer’s tangible and intangible assets and liabilities based on management’s preliminary estimate of their respective fair values as of July 16, 2013.
	Inventories		$	36,072
	Accounts receivable			10,567
	Other current assets			1,456
	Property, plant and equipment			15,258
	Other assets			12,148
	Current liabilities			(9,912	)
	Other long-term liabilities			(16,297	)
	Net tangible assets acquired			49,292
	Other intangible assets			23,800
	Goodwill			53,215
	Total net assets acquired		$	126,307
	Total net assets acquired as of July 16, 2013 are all part of the Company’s only operating segment. Fair values are based on management’s preliminary estimates and assumptions including variations of the income approach, the cost approach and the market approach.
	The Company believes that the acquisition of Pioneer offers the potential for substantial strategic and financial benefits. The transaction will enhance the Company’s existing core competency in biologics processing with the addition of Pioneer’s core competency in metals and synthetics. The Company believes the acquisition will enhance stockholder value through, among other things, enabling the Company to capitalize on the following strategic advantages and opportunities:
		•		Diversification of our implant portfolio.
		•		Expansion of our direct distribution and marketing organizations.
		•		Enhancement of our current international business.
		•		Improvement of our margin profile and revenue growth opportunities.
	These potential benefits resulted in the Company paying a premium for Pioneer resulting in the recognition of goodwill. The $53,215 of goodwill was assigned to the Company’s only operating segment.
	The fair value of receivables acquired is $10,567, with the gross contractual amount being $11,712, of which $1,145 was not expected to be collected.
	The amount of Pioneer’s revenues and net income since the July 16, 2013 acquisition date, included in the Company’s Condensed Consolidated Statements of Comprehensive (Loss) Income for the three months ended September 30, 2013 are $16,108 and $696, respectively.
	The following unaudited pro forma information shows the results of the Company’s operations as though the acquisition had occurred as of the beginning of that period (in thousands, except per share data):
			For the Three Months Ended					For the Nine Months Ended
			September			September		September			September
			2013			2012		2013			2012
	Revenues		$	57,788		$	65,677	$	182,495		$	198,449
	Net (loss) income			(1,088	)		2,827		(5,444	)		2,876
	Basic net (loss) income per share			(0.02	)		0.05		(0.10	)		0.05
	Diluted net (loss) income per share			(0.02	)		0.05		(0.10	)		0.05
	The pro forma results have been prepared for comparative purposes only and are not necessarily indicative of the actual results of operations had the merger taken place as of the beginning of the periods presented, or the results that may occur in the future.
	These amounts have been calculated to reflect the additional depreciation, amortization, and interest expense that would have been incurred assuming the fair value of adjustments and borrowings occurred on January 1, 2012 and January 1, 2013, together with the consequential tax effects. In addition, these amounts exclude costs incurred which are directly attributable to the acquisition, and which do not have a continuing impact on the combined companies’ operating results.
	The Company expects to complete its analysis of the purchase price allocation by the third quarter of 2014.

StockBased_Compensation

Stock-Based Compensation	9 Months Ended
	Sep. 30, 2013
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Stock-Based Compensation	'
	5	Stock-Based Compensation
	As of September 30, 2013, the Company has five stock-based compensation plans under which employees, consultants and outside directors have received stock options and restricted stock awards. The Company’s policy is to grant stock options at an exercise price equal to 100% of the market value of a share of common stock at closing on the date of the grant. Stock options generally have ten-year contractual terms and vest over a one to five year period from the date of grant. The Company’s policy is to grant restricted stock awards at a fair value equal to 100% of the market value of a share of common stock at closing on the date of the grant. Restricted stock awards generally vest over one to three year periods.
	1998 Stock Option Plan, 2004 Equity Incentive Plan and 2010 Equity Incentive Plan – The Company adopted equity incentive plans in 1998 (the “1998 Plan”), 2004 (the “2004 Plan”) and 2010 (the “2010 Plan”), which provide for the grant of incentive and nonqualified stock options and restricted stock to key employees, including officers and directors of the Company and consultants and advisors. The 1998 Plan, 2004 Plan and 2010 Plan allow for up to 4,406,400, 2,000,000 and 5,000,000 shares, respectively, of common stock to be issued with respect to awards granted. New stock options may no longer be awarded under the 1998 Plan.
	TMI 1996 Stock Option Plan and TMI 2006 Incentive and Non-Statutory Stock Option Plan – In connection with the merger with TMI, the Company assumed the TMI 1996 Stock Option Plan and the TMI 2006 Incentive and Non-Statutory Stock Option Plan (“TMI Plans”). The TMI Plans allow for 4,880,000 and 1,830,000 shares of common stock, respectively, which may be issued with respect to stock options granted to former TMI employees or employees of the Company hired subsequent to the TMI acquisition. New stock options may no longer be awarded under the TMI 1996 Stock Option Plan.
	Stock Options
	As of September 30, 2013, there was $3,355 of total unrecognized stock-based compensation related to nonvested stock options. That expense is expected to be recognized over a weighted-average period of 3.22 years.
	Stock options outstanding, exercisable and available for grant at September 30, 2013 are summarized as follows:
			Number of			Weighted		Weighted		Aggregate
			Shares			Average		Average		Intrinsic
						Exercise		Remaining		Value
						Price		Contractual
								Life (Years)
	Outstanding at January 1, 2013			5,083,834		$	5.03
	Granted			866,500			3.6
	Exercised			(109,790	)		3.01
	Forfeited or expired			(478,040	)		6.76
	Outstanding at September 30, 2013			5,362,504		$	4.69		5.84	$	1,336
	Vested or expected to vest at September 30, 2013			5,208,154		$	4.72		5.76	$	1,306
	Exercisable at September 30, 2013			3,214,604		$	5.42		4.35	$	740
	Available for grant at September 30, 2013			2,908,953
	Other information concerning stock options are as follows:
			Nine Months Ended
			September 30,
			2013			2012
	Weighted average fair value of stock options granted		$	1.72		$	2.43
	Aggregate intrinsic value of stock options exercised			117			184
	The aggregate intrinsic value in the preceding tables above represent the total pre-tax intrinsic value of outstanding stock options for which the fair market value of the underlying common stock exceeds the respective stock option exercise price.
	Restricted Stock Awards
	During the first quarter of 2013, the Company granted 145,000 shares of restricted stock with a weighted-average grant date fair value of $3.60 per share which vest over a three year period. During the second quarter of 2013, the Company granted 116,311 shares of restricted stock with a weighted-average grant date fair value of $3.74 per share which vest over a one year period. During the third quarter of 2013, the Company granted 29,268 shares of restricted stock with a weighted-average grant date fair value of $4.10 per share which vest over a one year period. As of September 30, 2013, there was $1,001 of total unrecognized stock-based compensation related to time-based, nonvested restricted stock. That expense is expected to be recognized on a straight-line basis over a weighted-average period of 1.38 years.
	For the three and nine months ended September 30, 2013 and 2012, the Company recognized stock-based compensation as follows:
			Three Months Ended					Nine Months Ended
			September 30,					September 30,
			2013			2012		2013		2012
	Stock-based compensation:
	Costs of processing and distribution		$	33		$	56	$	99	$	172
	Marketing, general and administrative			536			452		1,509		1,355
	Research and development			15			16		45		47
	Total		$	584		$	524	$	1,653	$	1,574

Net_Loss_Income_Per_Common_Sha

Net (Loss) Income Per Common Share	9 Months Ended
	Sep. 30, 2013
Earnings Per Share [Abstract]	'
Net (Loss) Income Per Common Share	'
	6	Net (Loss) Income Per Common Share
	A reconciliation of the number of shares of common stock used in the calculation of basic and diluted net (loss) income per common share is presented below:
			Three Months Ended				Nine Months Ended
			September 30,				September 30,
			2013		2012		2013		2012
	Basic shares			56,356,885		55,908,574		56,216,200		55,826,306
	Effect of dilutive securities:
	Stock options			—		202,324		—		187,235
	Diluted shares			56,356,885		56,110,898		56,216,200		56,013,541
	For the three months ended September 30, 2013 and 2012, approximately 4,019,882 and 3,912,000, respectively, and for the nine months ended September 30, 2013 and 2012, approximately 4,004,972 and 4,247,000, respectively, of issued stock options were not included in the computation of diluted net income or loss per common share because they were anti-dilutive since their exercise price exceeded their market price. For the three and nine months ended September 30, 2013, options to purchase 262,695 and 276,164 shares of common stock, respectively, were not included in the computation of diluted EPS because dilutive shares are not factored into the calculation of EPS when a net loss is reported. Additionally, for the three and nine months ended September 30, 2012 options to purchase 202,324 and 187,235 shares of common stock, respectively, were included in the computation of diluted EPS because dilutive shares are factored into the calculation of EPS when net income is reported.
	For the three and nine months ended September 30, 2013, 50,000 shares of convertible preferred stock were anti-dilutive on an as if-converted basis and were not included in the computation of diluted net loss per common share.

Inventories

Inventories	9 Months Ended
	Sep. 30, 2013
Inventory Disclosure [Abstract]	'
Inventories	'
	7	Inventories
	Inventories by stage of completion are as follows:
			September 30,		December 31,
			2013		2012
	Unprocessed tissue and raw materials		$	31,775	$	25,962
	Tissue and work in process			39,839		28,379
	Implantable tissue and finished goods			39,493		20,071
	Supplies			2,031		2,097
			$	113,138	$	76,509
	For the three months ended September 30, 2013 and 2012, the Company had inventory write-downs of $552 and $617, respectively, and for the nine months ended September 30, 2013 and 2012, the Company had inventory write-downs of $1,898 and $3,100, respectively, relating primarily to product obsolescence.

Property_Plant_and_Equipment

Property, Plant and Equipment	9 Months Ended
	Sep. 30, 2013
Property Plant And Equipment [Abstract]	'
Property, Plant and Equipment	'
	8	Property, Plant and Equipment
	Property, plant and equipment are as follows:
			September 30,			December 31,
			2013			2012
	Land		$	2,596		$	2,169
	Buildings and improvements			49,332			45,220
	Processing equipment			42,665			31,681
	Surgical instruments			4,527			—
	Office equipment, furniture and fixtures			3,836			2,831
	Computer equipment and software			6,152			5,029
	Construction in process			13,650			7,329
	Equipment under capital leases:
	Processing equipment			396			396
	Computer equipment			896			744
				124,050			95,399
	Less accumulated depreciation			(51,232	)		(45,755	)
			$	72,818		$	49,644
	Depreciation expense of property, plant and equipment was $2,644 and $1,528 for the three months ended September 30, 2013 and 2012, respectively, and $5,716 and $4,395 for the nine months ended September 30, 2013 and 2012, respectively.

Goodwill

Goodwill	9 Months Ended
	Sep. 30, 2013
Goodwill And Intangible Assets Disclosure [Abstract]	'
Goodwill	'
	9	Goodwill
			September 30,		December 31,
			2013		2012
	Balance at January 1		$	2,062	$	—
	Goodwill acquired during the period			53,215		2,062
			$	55,277	$	2,062
	Goodwill acquired during 2013 includes the excess of the Pioneer purchase price over the sum of the amounts assigned to assets acquired less liabilities assumed.

Other_Intangible_Assets

Other Intangible Assets	9 Months Ended
	Sep. 30, 2013
Goodwill And Intangible Assets Disclosure [Abstract]	'
Other Intangible Assets	'
	10	Other Intangible Assets
	Other intangible assets are as follows:
			September 30, 2013				December 31, 2012
			Gross				Gross
			Carrying		Accumulated		Carrying		Accumulated
			Amount		Amortization		Amount		Amortization
	Patents		$	10,163	$	1,749	$	4,616	$	1,443
	Acquired exclusivity rights			2,941		2,694		2,941		2,415
	Acquired licensing rights			10,850		5,023		10,850		4,115
	Marketing and procurement intangible assets			22,791		1,835		4,223		891
	Total		$	46,745	$	11,301	$	22,630	$	8,864
	Marketing and procurement intangible assets include the following: procurement contracts, trademarks, selling and marketing relationships, customer lists, and non-compete agreements.
	Amortization expense of other intangible assets for the three months ended September 30, 2013 and 2012 was $1,447 and $507, respectively, and for the nine months ended September 30, 2013 and 2012 was $2,498 and $1,519, respectively. At September 30, 2013, management’s estimates of future amortization expense for the next five years are as follows:
			Amortization
			Expense
	2013		$	1,500
	2014			4,400
	2015			4,100
	2016			3,600
	2017			3,600
			$	17,200

Other_Assets

Other Assets	9 Months Ended
	Sep. 30, 2013
Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]	'
Other Assets	'
	11	Other Assets
	Other assets are as follows:
			September 30,		December 31,
			2013		2012
	Indemnification asset		$	13,000	$	—
	Other			1,276		713
			$	14,276	$	713
	Other assets include $13,000 of indemnification assets recognized on the date of the acquisition of Pioneer. Under the acquisition agreement, Pioneer deposited $13,000 in an escrow account and indemnified the Company for up to $13,000 for various outstanding legal issues as of September 30, 2013. In conjunction with recording the indemnification asset, the Company also recorded a corresponding $13,000 indemnification liability.
	For the three and nine months ended September 30, 2013 and 2012, the Company recognized interest expense associated with the amortization of its debt issuance costs which is included in Other in the table above of $36 and $4 and of $42 and $20, respectively.

Accrued_Expenses

Accrued Expenses	9 Months Ended
	Sep. 30, 2013
Other Liabilities Disclosure [Abstract]	'
Accrued Expenses	'
	12	Accrued Expenses
	Accrued expenses are as follows:
			September 30,		December 31,
			2013		2012
	Accrued compensation		$	6,703	$	6,279
	Accrued donor recovery fees			5,489		3,845
	Accrued taxes			111		3,950
	Contingent consideration			139		900
	Other			7,121		5,620
			$	19,563	$	20,594
	The Company accrues for the estimated donor recovery fees due to third party recovery agencies as tissue is received.

Short_and_LongTerm_Obligations

Short and Long-Term Obligations	9 Months Ended
	Sep. 30, 2013
Debt Disclosure [Abstract]	'
Short and Long-Term Obligations	'
	13	Short and Long-Term Obligations
	Short and long-term obligations are as follows:
			September 30,			December 31,
			2013			2012
	Term loan		$	60,000		$	—
	Credit facilities			8,250			—
	Capital leases			160			120
	Total			68,410			120
	Less current portion			(28	)		(116	)
	Long-term portion		$	68,382		$	4
	On July 16, 2013, the Company obtained from TD Bank and Regions Bank, a 5 year, $80,000 senior secured facility, which includes a $60,000 term loan and a $20,000 revolving credit facility, that matures on July 16, 2018 with a variable interest rate between 100 and 175 basis points in excess of the one month LIBOR rate. At September 30, 2013, the interest rate for the term loan and revolving credit facility is 1.68%. The facility is secured by substantially all the assets of the Company and its subsidiaries and guaranteed by the Company’s domestic subsidiaries, other than RTI Donor Services, Inc. The $20,000 revolving credit facility replaced the Company’s previous $15,000 U.S. credit facility. The term loan facility includes an interest only period of September 30, 2013 through December 31, 2014 with a final balloon principal payment at the end of the loan agreement. The new credit agreement also contains various restrictive covenants which limit, among other things, indebtedness and liens, require a minimum cash balance on hand of $10,000, and require certain financial covenant ratios.
	In addition to the credit facility with TD Bank and Regions Bank, the Company has three credit facilities with German banks as of September 30, 2013. The total available credit on the Company’s four revolving credit facilities at September 30, 2013 was $14,049. As of September 30, 2013, there was $8,250 outstanding on the revolving credit facility with TD Bank and Regions Bank.
	Under the terms of the revolving credit facilities with three German banks, the Company may borrow up to 1,700 Euro, or approximately $2,299, for working capital needs. The 1,000 Euro revolving credit facility is secured by a mortgage on the Company’s German facility. The 500 Euro revolving credit facility is secured by accounts receivable of the Company’s German subsidiary. The 200 Euro revolving credit facility is unsecured. The current interest rates for these lines of credit vary from 3.30% to 6.00%.
	The Company was in compliance with all covenants related to its revolving credit facilities as of September 30, 2013.
	The Company has capital leases with interest rates ranging from 1.49% to 8.46% and maturity dates of 2017 and beyond.
	As of September 30, 2013, contractual maturities of long-term obligations are as follows:
			Term Loan			Credit			Capital		Total
						Facilities			Leases
	2013		$	—		$	—		$	20	$	20
	2014			625			—			58		683
	2015			5,250			—			44		5,294
	2016			4,500			—			32		4,532
	2017 and beyond			49,625			8,250			6		57,881
			$	60,000		$	8,250		$	160	$	68,410
	The $160 representing future maturities of capital leases includes interest in the amount of $8. The present value of net minimum lease payments as of September 30, 2013 was $152.

Other_LongTerm_Liabilities

Other Long-Term Liabilities	9 Months Ended
	Sep. 30, 2013
Text Block [Abstract]	'
Other Long-Term Liabilities	'
	14	Other Long-Term Liabilities
	Other long-term liabilities are as follows:
			September 30,		December 31,
			2013		2012
	Indemnification liability		$	13,000	$	—
	Other			1,626		698
			$	14,626	$	698
	As described in Note 11, the Company recorded a $13,000 indemnification liability on the date of the acquisition of Pioneer.

Income_Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2013
Income Tax Disclosure [Abstract]	'
Income Taxes	'
	15	Income Taxes
	The Company expects its deferred tax assets of $24,952, net of the valuation allowance at September 30, 2013 of $469, to be realized through the generation of future taxable income and the reversal of existing taxable temporary differences.
	Valuation allowances are established when necessary to reduce deferred tax assets to amounts which are more likely than not to be realized. As such, valuation allowances of $469 have been established at both September 30, 2013 and December 31, 2012, against a portion of the Company’s deferred tax assets relating to certain state net operating loss carryforwards.
	The Company has state net operating loss carryforwards of $12,467 that will expire in the years 2018 and 2022 through 2024.
	On January 2, 2013 the American Taxpayer Relief Act of 2012 (“ATRA”) was signed into law. The ATRA retroactively extended the research tax credit to the beginning of 2012 through 2013. Under ASC 740, Accounting for Income Taxes, the effects of the tax legislation are recognized upon enactment. Therefore, the Company recognized the tax benefit during the first quarter of 2013.
	United States income taxes have not been provided on the undistributed earnings of the Company’s German subsidiary. It is not practicable to estimate the amount of tax that might be payable. The Company’s intention is to permanently reinvest earnings in its German subsidiary. As of December 31, 2012 and September 30, 2013, the amount of undistributed earnings related to our foreign subsidiaries considered to be indefinitely reinvested was $10,364 and $8,486, respectively.
	One of the Company’s foreign subsidiaries is undergoing an examination by the German tax authorities. The foreign examination covers the foreign subsidiary’s 2006 through 2009 tax years. In addition, the Company is undergoing an examination by the Internal Revenue Service (“IRS”). The IRS examination covers the 2010 tax year.

Preferred_Stock

Preferred Stock	9 Months Ended
	Sep. 30, 2013
Equity [Abstract]	'
Preferred Stock	'
	16	Preferred Stock
	Preferred stock is as follows:
			September 30,			December 31,
			2013			2012
	Preferred shares issuance		$	50,000		$	—
	Preferred shares issuance costs			(1,290	)		—
	Net proceeds			48,710			—
	Amortization of preferred shares issuance costs			46			—
	Accrued dividend payable			625			—
			$	49,381		$	—
	On June 12, 2013, the Company and WSHP entered into an investment agreement. Pursuant to the terms of the investment agreement, the Company agreed to a $50,000 private placement of convertible preferred equity with WSHP. In connection with the closing of the transactions contemplated by the investment agreement, the Company and WSHP amended the investment agreement on July 15, 2013, and the Company filed a Certificate of Designation of Series A Convertible Preferred Stock creating the Series A Convertible Preferred Stock, par value $0.001 per share (the “Preferred Stock”), and establishing the designations, preferences, and other rights of the Preferred Stock. The Preferred Stock will accrue dividends at a rate of 6% per annum, subject to adjustment to 12% per annum if the Company does not obtain the stockholder approval in accordance with Nasdaq listing rules within 180 days following the date of issuance of the Preferred Stock, payable in cash on a quarterly basis for each outstanding share of Preferred Stock. To the extent dividends are not paid in cash in any quarter, the dividends which have accrued on each outstanding share of Preferred Stock during such three-month period shall be accumulated and shall remain accumulated dividends with respect to such share of Preferred Stock until paid in cash.
	The Preferred Stock will be convertible at the election of the holders into shares of the Company’s common stock at an initial conversion price of $4.39 per share which would result in a conversion ratio of approximately 228 shares of common stock for every one share of preferred stock following the receipt of the stockholder approval. If such approval is not obtained, the Preferred Stock shall not be convertible into more than 19.99% of shares of Common Stock outstanding immediately prior to the date of issuance of the Preferred Stock. The Preferred Stock will be convertible at the election of the Company five years after its issuance or at any time if the Company’s common stock closes at or above $7.98 per share for at least 20 consecutive trading days.
	The Company may, upon 30 days notice, redeem the Preferred Stock, in whole or in part, five years after its issuance at the initial liquidation preference of $1,000 per share of the Preferred Stock plus an amount per share equal to accrued but unpaid dividends (collectively, the “Liquidation Value”). The holders of the Preferred Stock may require the Company to redeem their Preferred Stock, in whole or in part, at the Liquidation Value seven years after its issuance or upon the occurrence of a change of control.

Supplemental_Disclosures_of_Ca

Supplemental Disclosures of Cash Flow and Noncash Investing and Financing Activities	9 Months Ended
	Sep. 30, 2013
Supplemental Cash Flow Elements [Abstract]	'
Supplemental Disclosures of Cash Flow and Noncash Investing and Financing Activities	'
	17	Supplemental Disclosures of Cash Flow and Noncash Investing and Financing Activities
	Selected cash payments, receipts, and noncash activities are as follows:
			Three Months Ended				Nine Months Ended
			September 30,				September 30,
			2013		2012		2013		2012
	Cash paid for interest		$	246	$	6	$	249	$	19
	Income taxes paid			286		288		3,840		2,659
	Change in tax benefit from stock-based compensation			120		410		120		197
	Change in accrual for purchases of property, plant and equipment			2,035		74		2,835		188
	Change in accrual for acquired intangible asset costs			808		1,275		668		1,439
	Accrued dividend payable			625		—		625		—

Segment_Data

Segment Data	9 Months Ended
	Sep. 30, 2013
Segment Reporting [Abstract]	'
Segment Data	'
	18	Segment Data
	The Company processes human and bovine animal tissue, manufactures metal and synthetic products and distributes the tissue and products through various distribution channels. The Company operates in one reportable segment comprised of six lines of business. The Company’s lines of business are comprised primarily of six implant categories: spine, sports medicine, surgical specialties, bone graft substitutes (“BGS”) and general orthopedic, dental and ortho fixation. Discrete financial information is not available for these six lines of business. The following table presents revenues from tissue and product distribution, and other revenues for the three and nine months ended September 30, 2013 and 2012, respectively:
			Three Months Ended						Nine Months Ended
			September 30,						September 30,
			2013			2012			2013			2012
	Revenues from tissue distribution:
	Spine		$	17,600		$	10,187		$	38,920		$	28,532
	Sports medicine			9,532			11,811			31,700			38,573
	Surgical specialties			6,730			7,880			20,559			24,136
	BGS and general orthopedic			7,692			7,916			19,093			21,947
	Dental			4,963			5,240			14,142			15,678
	Ortho fixation			6,704			—			6,704			—
	Other revenues			1,521			1,532			6,355			4,640
	Total revenues		$	54,742		$	44,566		$	137,473		$	133,506
	Domestic revenues			49,295			39,643			122,822			116,707
	International revenues			5,447			4,923			14,651			16,799
	Total revenues		$	54,742		$	44,566		$	137,473		$	133,506
	The following table presents percentage of total revenues derived from the Company’s largest distributors and international distribution:
			Three Months Ended						Nine Months Ended
			September 30,						September 30,
			2013			2012			2013			2012
	Percent of revenues derived from:
	Distributor
	Medtronic, Inc.			14	%		19	%		17	%		18	%
	Zimmer, Inc.			19	%		15	%		17	%		14	%
	Davol, Inc.			8	%		12	%		10	%		12	%
	International			10	%		11	%		11	%		13	%
	The following table presents property, plant and equipment - net by significant geographic location:
			September 30,			December 31,
			2013			2012
	Property, plant and equipment - net:
	Domestic		$	56,984		$	34,637
	International			15,834			15,007
	Total		$	72,818		$	49,644

Commitments_and_Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2013
Commitments And Contingencies Disclosure [Abstract]	'
Commitments and Contingencies	'
	19	Commitments and Contingencies
	Acquisition Agreement with Third Party Donor Recovery Agency - On December 28, 2012, RTIDS acquired certain assets related to the tissue procurement operations of a third party donor recovery agency. Under the terms of the asset transfer agreement, the maximum purchase price is $3,900 in cash, of which $3,000 was paid at closing. In addition to the $3,000 closing payment, RTIDS agreed to pay the third party donor recovery agency up to an additional $900 in connection with the assignment to RTIDS of contracts with designated hospitals and medical examiners, of which RTIDS paid $761 through the third quarter of 2013. The remaining balance of the contingent payment is recorded in accrued expenses and within thirty days following the end of each calendar quarter during 2013, RTIDS shall pay the third party donor recovery agency the additional closing costs for the designated hospital contracts assigned or relationships transferred during the quarter for which the applicable payment is due.
	Dental Distribution Agreement with Zimmer—On September 3, 2010, the Company and Zimmer Dental Inc. (“Zimmer”), a subsidiary of Zimmer, Inc., entered into an exclusive distribution agreement (the “Agreement”), with an effective date of September 30, 2010. The Agreement has an initial term of ten years. Under the terms of the Agreement, the Company has agreed to supply sterilized allograft and xenograft implants at an agreed upon transfer price, and Zimmer has agreed to be the exclusive distributor of the implants for dental and oral applications worldwide (except the Ukraine), subject to certain Company obligations under an existing distribution agreement with a third party with respect to certain implants for the dental market. In consideration for Zimmer’s exclusive distribution rights, Zimmer agreed to the following: 1) payment to the Company of $13,000 within ten days of the effective date (“the Upfront Payment”), 2) annual exclusivity fees (“Annual Exclusivity Fees”) paid annually for the term of the contract to be paid at the beginning of each calendar year, and, 3) escalating annual purchase minimums to maintain exclusivity. Upon occurrence of an event that materially and adversely affects Zimmer’s ability to distribute the implants, Zimmer may be entitled to certain refund rights with respect to the Upfront Payment and the then current Annual Exclusivity Fee, where such refund would be in an amount limited by a formula specified in the Agreement that is based substantially on the number of days from the occurrence of such event to the date that it is cured by the Company to the satisfaction of Zimmer. The Upfront Payment, the Annual Exclusivity Fees and the fees associated with distributions of processed tissue are considered to be a single unit of accounting. Accordingly, the Upfront Payment and the Annual Exclusivity Fees are deferred as received and are being recognized as other revenues over the term of the Agreement based on the expected contractual escalating annual purchase minimums relative to the total contractual minimum purchase requirements in the Agreement. Additionally, the Company has considered the potential impact of the Agreement’s contractual refund provisions and does not expect these provisions to impact future expected revenue related to the Agreement.
	Exclusive License Agreement with Athersys—On September 10, 2010, the Company entered into an Exclusive License Agreement with Athersys, Inc. (“Athersys”), pursuant to which Athersys will provide the Company access to its Multipotent Adult Progenitor Cell (“MAPC”) technologies to develop and commercialize MAPC technology-based biologic implants for certain orthopedic applications. In consideration for the Exclusive License, the Company agreed to pay Athersys the following: 1) a non-refundable $3,000 license fee, payable in three time-based $1,000 installments, the last of which was paid in the first quarter of 2011, 2) payment of $2,000 contingent upon successful achievement of certain development milestones which the Company paid in 2012, and 3) up to $32,500 contingent upon achievement of certain cumulative revenue milestones in future years. In addition, the Company will pay Athersys royalties from the distribution of implants under a tiered royalty structure based on achievement of certain cumulative revenue milestones. The term of the Exclusive License Agreement is the longer of five years, or the remaining life of any patent or trade secret. These acquired licensing rights are being amortized to expense on a straight-line basis over the expected life of the asset.
	Distribution Agreement with Davol—On July 13, 2009, the Company and Davol amended their previous distribution agreement with TMI for human dermis implants. Under the amended agreement, 1) Davol paid the Company $8,000 in non-refundable fees for exclusive distribution rights for the distribution to the breast reconstruction market until July 13, 2019, 2) the exclusive worldwide distribution agreement related to the hernia market was extended to July 13, 2019, and 3) Davol agreed to pay the Company certain additional exclusive distribution rights fees contingent upon the achievement of certain revenue milestones by Davol during the duration of the contract. In the fourth quarter of 2010, Davol paid the first revenue milestone payment of $3,500. The non-refundable fees and the fees associated with distributions of processed tissue are considered to be a single unit of accounting. Accordingly, the $8,000 and $3,500 exclusivity payments have been deferred and are being recognized as other revenues on a straight-line basis over the initial term of the amended contract of ten years, and the remaining term of the amended contract, respectively. The straight-line method approximates the expected pattern of product distribution based on the distribution agreement’s contractual annual minimum purchase requirements. Davol did not achieve certain revenue growth milestones which resulted in Davol relinquishing its exclusive distribution rights in the hernia market effective January 1, 2013. As a result, the Company recognized $1,715 of additional deferred revenue as other revenues during the first quarter of 2013 due to the acceleration of deferred revenue recognition.
	BGS and General Orthopedic Distribution Agreement with Zimmer—On May 14, 2007, the Company entered into an exclusive distribution agreement with Zimmer with an initial term of ten years, relating to certain new bone graft substitutes implants. As part of the agreement, Zimmer made payments to the Company totaling $5,000 for the aforementioned exclusive distribution rights, and had to maintain certain minimum order volumes through the duration of the contract. The $5,000 exclusivity payment has been deferred and is being recognized as other revenue on a straight-line basis over the initial term of the contract. The contract provides for repayment, on a pro rata basis, of the exclusivity payments during the initial contract term for specific events of non-performance, as defined in the agreement. The agreement also included automatic two-year renewal terms, as well as buy-out provisions by both parties upon proper notice of cancellation. Effective May 30, 2012, the Company and Zimmer amended the agreement such that Zimmer retained exclusivity for dental and oral maxillofacial applications, and released exclusivity for other applications. Under the amended agreement, Zimmer is no longer required to maintain minimum order volumes, the Company is restricted from distributing the bone graft substitute implants into certain Zimmer accounts, and the buy-out provisions upon proper notice of cancellation were removed. No cash was exchanged between the Company and Zimmer and the term of the agreement remains unchanged. The exclusivity payment was not affected by the amendment to the agreement, which was not considered to be a material modification, and as such the revenue recognition remains unchanged.
	The Company’s aforementioned revenue recognition methods related to Davol and both Zimmer distribution agreements do not result in the deferral of revenue less than amounts that would be refundable in the event the agreements were to be terminated in future periods. Additionally, the Company evaluates the appropriateness of the aforementioned revenue recognition methods on an ongoing basis.
	Distribution Agreement with Medtronic, Inc. —The Company has a non-exclusive distribution agreement with Medtronic, Inc. (“Medtronic”) for specialty allograft and bone paste for use in spinal surgery. Medtronic does not make any significant upfront or periodic payments to the Company in conjunction with this agreement.
	Leases—The Company leases certain facilities, items of office equipment and vehicles under non-cancelable operating lease arrangements expiring on various dates beyond 2017. The facility leases generally contain renewal options and escalation clauses based upon increases in the lessors’ operating expenses and other charges. The Company anticipates that most of these leases will be renewed or replaced upon expiration. At September 30, 2013, the aggregate future minimum lease payments under all non-cancelable lease agreements were as follows:
			Operating
			Leases
	2013		$	559
	2014			1,685
	2015			739
	2016			248
	2017 and beyond			148
			$	3,379
	Legal and Regulatory Actions—The Company is, from time to time, involved in litigation relating to claims arising out of its operations in the ordinary course of business. The Company believes that none of these claims that were outstanding as of September 30, 2013 will have a material adverse impact on its financial position or results of operations.
	Biomedical Tissue Service, Ltd.—The Company was named as a party, along with a number of other recovery and processor defendants, in lawsuits relating to the tissue recovery practices of Biomedical Tissue Service, Ltd. (“BTS”), an unaffiliated recovery agency and BTS’s owner, the late, Michael Mastromarino, as well as several funeral homes and their owners with which BTS conducted its activities. These cases generally alleged that the Company had liability for interference with the rights of the surviving next of kin as perpetrated by BTS and the funeral homes. As a result of increased judicial clarity during the second quarter of 2012 regarding timing of litigation, and anticipated increases in legal activity and expense flowing therefrom, the Company determined that the cost of continuing an aggressive legal defense for certain of the lawsuits would be significant. Therefore, in order to mitigate the Company’s financial exposure, an agreement was reached to settle 29 of the lawsuits for which our insurer was not paying for the legal fees. Pursuant to the settlement of these lawsuits, the Company recorded a litigation settlement charge of $2,350 in the second quarter of 2012 which was paid in the third quarter of 2012.
	The Company, through its affiliation with RTIDS, currently has $2,000 in answerable indemnity insurance, with non-eroding defense limits. On July 25, 2013, the Company and attorneys for the majority of the remaining donor family cases signed an agreement to settle those cases for an upfront payment of $2,700 with a contingent interest in any recovery in the Company’s litigation with its insurer, in the amount of $300. In the event the $300 has not been recovered from the insurance company by January 15, 2015, the Company will guarantee its payment. Pursuant to the settlement of these lawsuits, the Company recorded a litigation settlement charge of $3,000 in the second quarter of 2013. The resolution of these cases related to BTS effectively brought to conclusion any reasonable probability for materially adverse impact on our business, financial conditions, or results of operations.
	Lanx, Inc. filed suit in the second quarter of 2013 against Pioneer in the United States District Court, District of Colorado, alleging that one of the Company’s medical devices infringes certain of Lanx’s United States intellectual property rights, and seeking monetary damages and threatening injunctive relief. The parties are currently in discovery and litigation is ongoing. The Company has given notice to the former Pioneer stockholders’ agent of an indemnification claim against the Pioneer escrow fund. The Company denies the allegations of infringement, believes it has meritorious defenses, and intends to vigorously defend itself.
	The Company’s accounting policy is to accrue for legal costs as they are incurred.
	On October 23, 2012, the Company received a warning letter from the U.S. Food and Drug Administration (“FDA”) related to environmental monitoring activities in certain areas of its processing facility in Alachua, Florida. The FDA re-inspected the processing facility in Alachua, Florida in September 2013 and determined that the Company had addressed the FDA’s concerns from the previous inspection. On October 29, 2013, the Company received a final close out letter from the FDA to formally resolve their concerns. The warning letter did not restrict the Company’s ability to process or distribute implants, nor did it require the withdrawal of any implants from the marketplace.

Related_Parties

Related Parties	9 Months Ended
	Sep. 30, 2013
Related Party Transactions [Abstract]	'
Related Parties	'
	20	Related Parties
	From October 2012 through April 2013, the Chairman of the Company’s board of directors was Interim Chief Financial Officer of Stryker Corporation (“Stryker”). Effective May 2013, the Chairman of the Company’s board of directors resumed his previous role as Vice President, Corporate Secretary of Stryker. The Company has a spine distribution agreement, with one year automatic renewals in June, and a BGS and general orthopedic distribution agreement, with two year automatic renewals in May, with Stryker.
	During the three months ended September 30, 2013 and 2012, the Company recognized revenues of $651 and $1,652, respectively, and during the nine months ended September 30, 2013 and 2012, the Company recognized revenues of $2,087 and $4,676, respectively, on distributions to Stryker. Distributions to Stryker for the three months ended September 30, 2013 and 2012 represented 1.2% and 3.7%, respectively, and for the nine months ended September 30, 2013 and 2012 represented 1.5% and 3.5%, respectively, of the Company’s total revenues. Trade accounts receivable due from Stryker totaled $402 and $552 at September 30, 2013 and December 31, 2012, respectively. Trade accounts payable due to Stryker totaled $94 and $18 at September 30, 2013 and December 31, 2012, respectively.

Subsequent_Events

Subsequent Events	9 Months Ended
	Sep. 30, 2013
Subsequent Events [Abstract]	'
Subsequent Events	'
	21	Subsequent Events
	The Company evaluated subsequent events as of the issuance date of the condensed consolidated financial statements, November 7, 2013, and determined that there were no applicable recognized events or transactions required to be recorded or disclosed in the financial statements, except for the following matters: on October 12, 2013, the Company entered into a replacement distribution agreement with Medtronic, pursuant to which Medtronic will distribute certain allograft implants for use in spinal, general orthopedic and trauma surgery. Under the terms of the agreement, Medtronic will be a non-exclusive distributor except for certain specified implants for which Medtronic will be the exclusive distributor. Medtronic will maintain its exclusivity with respect to these specified implants unless the cumulative fees received by us from Medtronic in respect of these specified implants decline by a certain amount during any trailing 12-month period. The initial term of the agreement will continue through December 31, 2017, unless earlier terminated in accordance with the agreement. This initial term will automatically renew for successive five-year periods, unless either party provides written notice of its intent not to renew at least one year prior to the expiration of the initial term or the applicable renewal period. The agreement supersedes and replaces our prior distribution agreement with Medtronic which would have expired in accordance with its terms in June 2014.
	On October 29, 2013, the Company received a final close out letter from the FDA to formally resolve their concerns. The warning letter did not restrict the Company’s ability to process or distribute implants, nor did it require the withdrawal of any implants from the marketplace.
	At a special meeting of stockholders held on November 7, 2013, the Company obtained stockholder approval in accordance with Nasdaq listing rules for the issuance of shares of the Company’s common stock upon conversion of the Series A Convertible Preferred Stock in excess of 19.99% of the common stock outstanding prior to such issuance. The Series A Convertible Preferred Stock will continue to accrue dividends at a rate of 6% per annum.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2013
Accounting Policies [Abstract]	'
Cash and Cash Equivalents	'
	Cash and Cash Equivalents—The Company considers all funds in banks and short-term highly liquid investments with an original maturity of three months or less to be cash and cash equivalents. Cash equivalents comprise overnight repurchase agreements. Cash balances are held at a few financial institutions and usually exceed insurable amounts. The Company mitigates this risk by depositing its uninsured cash in major well capitalized financial institutions, and by investing excess operating cash in overnight repurchase agreements which are 101% collateralized by U.S. Government backed securities with the Company’s bank. At September 30, 2013, the Company had no cash equivalents as the full balance of cash and cash equivalents was held as cash. At December 31, 2012, the Company had $6,667 of overnight repurchase agreements in cash equivalents, which represent less than 3% and 4% of the Company’s total assets and equity, respectively.
Income Taxes	'
	On January 2, 2013 the American Taxpayer Relief Act of 2012 (“ATRA”) was signed into law. The ATRA retroactively extended the research tax credit to the beginning of 2012 through 2013. Under ASC 740, Accounting for Income Taxes, the effects of the tax legislation are recognized upon enactment. Therefore, the Company recognized the tax benefit during the first quarter of 2013.

Merger_with_Pioneer_Surgical_T1

Merger with Pioneer Surgical Technology, Inc. (Tables)	9 Months Ended
	Sep. 30, 2013
Business Combinations [Abstract]	'
Summary of Purchase Price	'
	The preliminary purchase price was financed as follows:
		(In thousands)
	Cash proceeds from term loan	$	60,000
	Net cash proceeds from preferred share issuance		48,710
	Cash from RTI Surgical		17,597
	Total purchase price	$	126,307
Allocation of the Total Consideration of Tangible and Intangible Assets and Liabilities	'
	The table below represents a preliminary allocation of the total consideration to Pioneer’s tangible and intangible assets and liabilities based on management’s preliminary estimate of their respective fair values as of July 16, 2013.
	Inventories	$	36,072
	Accounts receivable		10,567
	Other current assets		1,456
	Property, plant and equipment		15,258
	Other assets		12,148
	Current liabilities		(9,912	)
	Other long-term liabilities		(16,297	)
	Net tangible assets acquired		49,292
	Other intangible assets		23,800
	Goodwill		53,215
	Total net assets acquired	$	126,307
Unaudited Pro Forma Information of the Company's Operations	'
	The following unaudited pro forma information shows the results of the Company’s operations as though the acquisition had occurred as of the beginning of that period (in thousands, except per share data):
		For the Three Months Ended					For the Nine Months Ended
		September			September		September			September
		2013			2012		2013			2012
	Revenues	$	57,788		$	65,677	$	182,495		$	198,449
	Net (loss) income		(1,088	)		2,827		(5,444	)		2,876
	Basic net (loss) income per share		(0.02	)		0.05		(0.10	)		0.05
	Diluted net (loss) income per share		(0.02	)		0.05		(0.10	)		0.05

StockBased_Compensation_Tables

Stock-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2013
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Stock Options Outstanding, Exercisable and Available for Grant	'
	Stock options outstanding, exercisable and available for grant at September 30, 2013 are summarized as follows:
		Number of			Weighted		Weighted		Aggregate
		Shares			Average		Average		Intrinsic
					Exercise		Remaining		Value
					Price		Contractual
							Life (Years)
	Outstanding at January 1, 2013		5,083,834		$	5.03
	Granted		866,500			3.6
	Exercised		(109,790	)		3.01
	Forfeited or expired		(478,040	)		6.76
	Outstanding at September 30, 2013		5,362,504		$	4.69		5.84	$	1,336
	Vested or expected to vest at September 30, 2013		5,208,154		$	4.72		5.76	$	1,306
	Exercisable at September 30, 2013		3,214,604		$	5.42		4.35	$	740
	Available for grant at September 30, 2013		2,908,953
Other Information Concerning Stock Options	'
	Other information concerning stock options are as follows:
		Nine Months Ended
		September 30,
		2013			2012
	Weighted average fair value of stock options granted	$	1.72		$	2.43
	Aggregate intrinsic value of stock options exercised		117			184
Stock-Based Compensation Recognized	'
	For the three and nine months ended September 30, 2013 and 2012, the Company recognized stock-based compensation as follows:
		Three Months Ended					Nine Months Ended
		September 30,					September 30,
		2013			2012		2013		2012
	Stock-based compensation:
	Costs of processing and distribution	$	33		$	56	$	99	$	172
	Marketing, general and administrative		536			452		1,509		1,355
	Research and development		15			16		45		47
	Total	$	584		$	524	$	1,653	$	1,574

Net_Loss_Income_Per_Common_Sha1

Net (Loss) Income Per Common Share (Tables)	9 Months Ended
	Sep. 30, 2013
Earnings Per Share [Abstract]	'
Reconciliation of Common Stock Used in Calculation of Basic and Diluted Earnings Per Share	'
	A reconciliation of the number of shares of common stock used in the calculation of basic and diluted net (loss) income per common share is presented below:
		Three Months Ended				Nine Months Ended
		September 30,				September 30,
		2013		2012		2013		2012
	Basic shares		56,356,885		55,908,574		56,216,200		55,826,306
	Effect of dilutive securities:
	Stock options		—		202,324		—		187,235
	Diluted shares		56,356,885		56,110,898		56,216,200		56,013,541

Inventories_Tables

Inventories (Tables)	9 Months Ended
	Sep. 30, 2013
Inventory Disclosure [Abstract]	'
Components of Inventories	'
	Inventories by stage of completion are as follows:
		September 30,		December 31,
		2013		2012
	Unprocessed tissue and raw materials	$	31,775	$	25,962
	Tissue and work in process		39,839		28,379
	Implantable tissue and finished goods		39,493		20,071
	Supplies		2,031		2,097
		$	113,138	$	76,509

Property_Plant_and_Equipment_T

Property, Plant and Equipment (Tables)	9 Months Ended
	Sep. 30, 2013
Property Plant And Equipment [Abstract]	'
Components of Property, Plant and Equipment	'
	Property, plant and equipment are as follows:
		September 30,			December 31,
		2013			2012
	Land	$	2,596		$	2,169
	Buildings and improvements		49,332			45,220
	Processing equipment		42,665			31,681
	Surgical instruments		4,527			—
	Office equipment, furniture and fixtures		3,836			2,831
	Computer equipment and software		6,152			5,029
	Construction in process		13,650			7,329
	Equipment under capital leases:
	Processing equipment		396			396
	Computer equipment		896			744
			124,050			95,399
	Less accumulated depreciation		(51,232	)		(45,755	)
		$	72,818		$	49,644

Goodwill_Tables

Goodwill (Tables)	9 Months Ended
	Sep. 30, 2013
Goodwill And Intangible Assets Disclosure [Abstract]	'
Goodwill	'
		September 30,		December 31,
		2013		2012
	Balance at January 1	$	2,062	$	—
	Goodwill acquired during the period		53,215		2,062
		$	55,277	$	2,062

Other_Intangible_Assets_Tables

Other Intangible Assets (Tables)	9 Months Ended
	Sep. 30, 2013
Goodwill And Intangible Assets Disclosure [Abstract]	'
Components of Other Intangible Assets	'
	Other intangible assets are as follows:
		September 30, 2013				December 31, 2012
		Gross				Gross
		Carrying		Accumulated		Carrying		Accumulated
		Amount		Amortization		Amount		Amortization
	Patents	$	10,163	$	1,749	$	4,616	$	1,443
	Acquired exclusivity rights		2,941		2,694		2,941		2,415
	Acquired licensing rights		10,850		5,023		10,850		4,115
	Marketing and procurement intangible assets		22,791		1,835		4,223		891
	Total	$	46,745	$	11,301	$	22,630	$	8,864
Estimates of Future Amortization Expense	'
	At September 30, 2013, management’s estimates of future amortization expense for the next five years are as follows:
		Amortization
		Expense
	2013	$	1,500
	2014		4,400
	2015		4,100
	2016		3,600
	2017		3,600
		$	17,200

Other_Assets_Tables

Other Assets (Tables)	9 Months Ended
	Sep. 30, 2013
Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]	'
Schedule of Other Assets	'
	Other assets are as follows:
		September 30,		December 31,
		2013		2012
	Indemnification asset	$	13,000	$	—
	Other		1,276		713
		$	14,276	$	713

Accrued_Expenses_Tables

Accrued Expenses (Tables)	9 Months Ended
	Sep. 30, 2013
Other Liabilities Disclosure [Abstract]	'
Accrued Expenses	'
	Accrued expenses are as follows:
		September 30,		December 31,
		2013		2012
	Accrued compensation	$	6,703	$	6,279
	Accrued donor recovery fees		5,489		3,845
	Accrued taxes		111		3,950
	Contingent consideration		139		900
	Other		7,121		5,620
		$	19,563	$	20,594

Short_and_LongTerm_Obligations1

Short and Long-Term Obligations (Tables)	9 Months Ended
	Sep. 30, 2013
Debt Disclosure [Abstract]	'
Short and Long-Term Obligations	'
	Short and long-term obligations are as follows:
		September 30,			December 31,
		2013			2012
	Term loan	$	60,000		$	—
	Credit facilities		8,250			—
	Capital leases		160			120
	Total		68,410			120
	Less current portion		(28	)		(116	)
	Long-term portion	$	68,382		$	4
Contractual Maturities of Long-Term Obligations	'
	As of September 30, 2013, contractual maturities of long-term obligations are as follows:
		Term Loan			Credit			Capital		Total
					Facilities			Leases
	2013	$	—		$	—		$	20	$	20
	2014		625			—			58		683
	2015		5,250			—			44		5,294
	2016		4,500			—			32		4,532
	2017 and beyond		49,625			8,250			6		57,881
		$	60,000		$	8,250		$	160	$	68,410

Other_LongTerm_Liabilities_Tab

Other Long-Term Liabilities (Tables)	9 Months Ended
	Sep. 30, 2013
Text Block [Abstract]	'
Schedule of Other Long-Term Liabilities	'
	Other long-term liabilities are as follows:
		September 30,		December 31,
		2013		2012
	Indemnification liability	$	13,000	$	—
	Other		1,626		698
		$	14,626	$	698

Preferred_Stock_Tables

Preferred Stock (Tables)	9 Months Ended
	Sep. 30, 2013
Equity [Abstract]	'
Schedule of Preferred Stock	'
	Preferred stock is as follows:
		September 30,			December 31,
		2013			2012
	Preferred shares issuance	$	50,000		$	—
	Preferred shares issuance costs		(1,290	)		—
	Net proceeds		48,710			—
	Amortization of preferred shares issuance costs		46			—
	Accrued dividend payable		625			—
		$	49,381		$	—

Supplemental_Disclosures_of_Ca1

Supplemental Disclosures of Cash Flow and Noncash Investing and Financing Activities (Tables)	9 Months Ended
	Sep. 30, 2013
Supplemental Cash Flow Elements [Abstract]	'
Selected Cash Payments, Receipts, and Noncash Activities	'
	Selected cash payments, receipts, and noncash activities are as follows:
		Three Months Ended				Nine Months Ended
		September 30,				September 30,
		2013		2012		2013		2012
	Cash paid for interest	$	246	$	6	$	249	$	19
	Income taxes paid		286		288		3,840		2,659
	Change in tax benefit from stock-based compensation		120		410		120		197
	Change in accrual for purchases of property, plant and equipment		2,035		74		2,835		188
	Change in accrual for acquired intangible asset costs		808		1,275		668		1,439
	Accrued dividend payable		625		—		625		—

Segment_Data_Tables

Segment Data (Tables)	9 Months Ended
	Sep. 30, 2013
Segment Reporting [Abstract]	'
Revenues from Tissue Distribution and Other Revenues	'
	The following table presents revenues from tissue and product distribution, and other revenues for the three and nine months ended September 30, 2013 and 2012, respectively:
		Three Months Ended						Nine Months Ended
		September 30,						September 30,
		2013			2012			2013			2012
	Revenues from tissue distribution:
	Spine	$	17,600		$	10,187		$	38,920		$	28,532
	Sports medicine		9,532			11,811			31,700			38,573
	Surgical specialties		6,730			7,880			20,559			24,136
	BGS and general orthopedic		7,692			7,916			19,093			21,947
	Dental		4,963			5,240			14,142			15,678
	Ortho fixation		6,704			—			6,704			—
	Other revenues		1,521			1,532			6,355			4,640
	Total revenues	$	54,742		$	44,566		$	137,473		$	133,506
	Domestic revenues		49,295			39,643			122,822			116,707
	International revenues		5,447			4,923			14,651			16,799
	Total revenues	$	54,742		$	44,566		$	137,473		$	133,506
Schedule of Percentage of Total Revenues Derived from Company's Largest Distributors and International Distribution	'
	The following table presents percentage of total revenues derived from the Company’s largest distributors and international distribution:
		Three Months Ended						Nine Months Ended
		September 30,						September 30,
		2013			2012			2013			2012
	Percent of revenues derived from:
	Distributor
	Medtronic, Inc.		14	%		19	%		17	%		18	%
	Zimmer, Inc.		19	%		15	%		17	%		14	%
	Davol, Inc.		8	%		12	%		10	%		12	%
	International		10	%		11	%		11	%		13	%
Schedule of Property, Plant and Equipment - Net by Significant Geographic Location	'
	The following table presents property, plant and equipment - net by significant geographic location:
		September 30,			December 31,
		2013			2012
	Property, plant and equipment - net:
	Domestic	$	56,984		$	34,637
	International		15,834			15,007
	Total	$	72,818		$	49,644

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	9 Months Ended
	Sep. 30, 2013
Commitments And Contingencies Disclosure [Abstract]	'
Aggregate Future Minimum Lease Payments Under all Non-Cancelable Lease Agreements	'
	At September 30, 2013, the aggregate future minimum lease payments under all non-cancelable lease agreements were as follows:
		Operating
		Leases
	2013	$	559
	2014		1,685
	2015		739
	2016		248
	2017 and beyond		148
		$	3,379

Operations_and_Organization_Ad

Operations and Organization - Additional Information (Detail)	9 Months Ended
	Sep. 30, 2013
	State
	Country
Operations And Organization [Line Items]	'
Number of states that receive distribution	50
Number of countries that receive distribution	45
Alachua, Florida [Member]	'
Operations And Organization [Line Items]	'
Number of operating facilities	2
Neunkirchen, Germany [Member]	'
Operations And Organization [Line Items]	'
Number of operating facilities	1

Summary_of_Significant_Account2

Summary of Significant Accounting Policies - Additional Information (Detail) (USD $)	9 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Dec. 31, 2012
Accounting Policies [Abstract]	'	'
Banks and short-term investments with an original maturity	'Three months or less	'
Cash and cash equivalents include overnight repurchase agreements backed by US Government securities	101.00%	'
Cash equivalents	$0	$6,667
Cash Equivalent Related to Overnight Repurchase Agreement Percentage of Total Assets	'	3.00%
Cash Equivalent Related to Overnight Repurchase Agreement Percentage of Equity	'	4.00%

Merger_with_Pioneer_Surgical_T2

Merger with Pioneer Surgical Technology, Inc. - Additional Information (Detail) (USD $)

3 Months Ended

9 Months Ended

1 Months Ended

3 Months Ended

9 Months Ended

9 Months Ended

9 Months Ended

In Thousands, unless otherwise specified

Sep. 30, 2013

Sep. 30, 2013

Jul. 16, 2013

Dec. 31, 2012

Jul. 16, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Pioneer [Member]

Pioneer [Member]

Pioneer [Member]

Pioneer [Member]

Pioneer [Member]

Pioneer [Member]

Pioneer [Member]

Pioneer [Member]

Pioneer [Member]

Pioneer [Member]

Senior Secured Facility [Member]

Bank Term Loan [Member]

Revolving Credit Facility [Member]

Minimum [Member]

Maximum [Member]

Operating Segments [Member]

Convertible Preferred Stock [Member]

Senior Secured Facility [Member]

Senior Secured Facility [Member]

Business Acquisition [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Business acquisition agreement date

'

'

'

'

'

'

12-Jun-13

'

'

'

'

'

'

'

Business acquisition cash consideration

$126,307

$126,307

'

'

$126,307

'

'

'

'

'

'

'

'

'

Business acquisition date

'

'

'

'

'

'

16-Jul-13

'

'

'

'

'

'

'

Term of senior secured credit facility

'

'

'

'

'

'

'

'5 years

'

'

'

'

'

'

Amount of senior secured facility obtained

'

'

'

'

'

80,000

80,000

'

60,000

20,000

'

'

'

'

Maturity date of senior secured credit facility

'

'

'

'

'

'

'

16-Jul-18

'

'

'

'

'

'

Variable interest rate, basis point

'

'

'

'

'

'

'

'

'

'

1.00%

1.75%

'

'

Existing credit facility amount replaced by new revolving credit facility

'

'

'

'

'

15,000

15,000

'

'

'

'

'

'

'

Proceeds from issuance of convertible preferred stock

'

'

'

'

'

'

50,000

'

'

'

'

'

'

'

Convertible preferred stock dividend rate

'

'

'

'

'

'

'

'

'

'

'

'

'

6.00%

Financing cost and expense

'

'

'

'

'

1,872

'

'

'

'

'

'

'

'

Acquisition costs expense

4,342

5,837

'

'

'

4,342,000

5,837,000

'

'

'

'

'

'

'

Goodwill assigned to operating segment

55,277

55,277

53,215

2,062

'

'

'

'

'

'

'

'

53,215

'

Fair value of receivables

'

'

'

'

'

10,567

10,567

'

'

'

'

'

'

'

Contractual amount, gross

'

'

'

'

'

11,712

11,712

'

'

'

'

'

'

'

Uncollected amount

'

'

'

'

'

1,145

1,145

'

'

'

'

'

'

'

Revenue

'

'

'

'

'

16,108

'

'

'

'

'

'

'

'

Net income

'

'

'

'

'

$696

'

'

'

'

'

'

'

'

Merger_with_Pioneer_Surgical_T3

Merger with Pioneer Surgical Technology, Inc. - Summary of Purchase Price (Detail) (USD $)	1 Months Ended
In Thousands, unless otherwise specified	Jul. 16, 2013
Business Combinations [Abstract]	'
Cash proceeds from term loan	$60,000
Net cash proceeds from preferred share issuance	48,710
Cash from RTI Surgical	17,597
Total purchase price	$126,307

Merger_with_Pioneer_Surgical_T4

Merger with Pioneer Surgical Technology, Inc. - Allocation of the Total Consideration of Tangible and Intangible Assets and Liabilities (Detail) (USD $)	Sep. 30, 2013	Jul. 16, 2013	Dec. 31, 2012	Dec. 28, 2012
In Thousands, unless otherwise specified
Business Combinations [Abstract]	'	'	'	'
Inventories	'	$36,072	'	'
Accounts receivable	'	10,567	'	'
Other current assets	'	1,456	'	'
Property, plant and equipment	'	15,258	'	'
Other assets	'	12,148	'	'
Current liabilities	'	-9,912	'	'
Other long-term liabilities	'	-16,297	'	'
Net tangible assets acquired	'	49,292	'	'
Other intangible assets	'	23,800	'	'
Goodwill	55,277	53,215	2,062	'
Total net assets acquired	'	$126,307	'	$3,900

Merger_with_Pioneer_Surgical_T5

Merger with Pioneer Surgical Technology, Inc. - Unaudited Pro Forma Information of the Company's Operations (Detail) (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Business Combinations [Abstract]	'	'	'	'
Revenues	$57,788	$65,677	$182,495	$198,449
Net (loss) income	($1,088)	$2,827	($5,444)	$2,876
Basic net (loss) income per share	($0.02)	$0.05	($0.10)	$0.05
Diluted net (loss) income per share	($0.02)	$0.05	($0.10)	$0.05

StockBased_Compensation_Additi

Stock-Based Compensation - Additional Information (Detail) (USD $)	3 Months Ended			9 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Sep. 30, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Contractual terms of stock options granted, in years	'	'	'	'10 years
Stock-based compensation plans, number	'	'	'	5
Percentage of market value of common stock, stock options exercise price	'	'	'	100.00%
Percentage of market value of common stock, restricted stock award granted	'	'	'	100.00%
1998 Stock Option Plan [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Shares of common stock to be issued with respect to awards granted	4,406,400	'	'	4,406,400
2004 Equity Incentive Plan [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Shares of common stock to be issued with respect to awards granted	2,000,000	'	'	2,000,000
2010 Equity Incentive Plan [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Shares of common stock to be issued with respect to awards granted	5,000,000	'	'	5,000,000
TMI 1996 Stock Option Plan [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Shares of common stock to be issued with respect to awards granted	4,880,000	'	'	4,880,000
TMI 2006 Incentive and Non Statutory Stock Option Plan [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Shares of common stock to be issued with respect to awards granted	1,830,000	'	'	1,830,000
Restricted Stock Awards [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Stock-based compensation award, vesting period	'1 year	'1 year	'	'
Total unrecognized stock-based compensation related to time-based, nonvested restricted stock	$1,001	'	'	$1,001
Weighted-average period recognized stock-based compensation	'	'	'	'1 year 4 months 17 days
Restricted stock granted during period	29,268	116,311	145,000	'
Weighted-average grant date fair value of restricted stock granted	$4.10	$3.74	$3.60	'
Restricted Stock Awards [Member] | Minimum [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Stock-based compensation award, vesting period	'	'	'	'1 year
Restricted Stock Awards [Member] | Maximum [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Stock-based compensation award, vesting period	'	'	'3 years	'3 years
Stock Options [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Total unrecognized stock-based compensation related to time-based, nonvested restricted stock	$3,355	'	'	$3,355
Weighted-average period recognized stock-based compensation	'	'	'	'3 years 2 months 19 days
Stock Options [Member] | Minimum [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Stock-based compensation award, vesting period	'	'	'	'1 year
Stock Options [Member] | Maximum [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Stock-based compensation award, vesting period	'	'	'	'5 years

StockBased_Compensation_Stock_

Stock-Based Compensation - Stock Options Outstanding, Exercisable and Available for Grant (Detail) (USD $)	9 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2013
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Outstanding, Number of Shares	5,083,834
Granted, Number of Shares	866,500
Exercised, Number of Shares	-109,790
Forfeited or expired, Number of Shares	-478,040
Outstanding, Number of Shares	5,362,504
Vested or expected to vest, Number of Shares	5,208,154
Exercisable, Number of Shares	3,214,604
Available for grant, Number of Shares	2,908,953
Outstanding, Weighted Average Exercise Price	$5.03
Granted, Weighted Average Exercise Price	$3.60
Exercised, Weighted Average Exercise Price	$3.01
Forfeited or expired, Weighted Average Exercise Price	$6.76
Outstanding, Weighted Average Exercise Price	$4.69
Vested or expected to vest, Weighted Average Exercise Price	$4.72
Exercisable, Weighted Average Exercise Price	$5.42
Outstanding, Weighted Average Remaining Contractual Life (Years)	'5 years 10 months 2 days
Vested or expected to vest, Weighted Average Remaining Contractual Life (Years)	'5 years 9 months 4 days
Exercisable, Weighted Average Remaining Contractual Life (Years)	'4 years 4 months 6 days
Outstanding, Aggregate Intrinsic Value	$1,336
Vested or expected to vest, Aggregate Intrinsic Value	1,306
Exercisable, Aggregate Intrinsic Value	$740

StockBased_Compensation_Other_

Stock-Based Compensation - Other Information Concerning Stock Options (Detail) (USD $)	9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'	'
Weighted average fair value of stock options granted	$1.72	$2.43
Aggregate intrinsic value of stock options exercised	$117	$184

StockBased_Compensation_StockB

Stock-Based Compensation - Stock-Based Compensation Recognized (Detail) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Stock-based compensation	$584	$524	$1,653	$1,574
Costs of Processing and Distribution [Member]	'	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Stock-based compensation	33	56	99	172
Marketing, General and Administrative [Member]	'	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Stock-based compensation	536	452	1,509	1,355
Research and Development [Member]	'	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Stock-based compensation	$15	$16	$45	$47

Net_Loss_Income_Per_Common_Sha2

Net (Loss) Income Per Common Share - Reconciliation of Common Stock Used in Calculation of Basic and Diluted Earnings per Share (Detail)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Earnings Per Share [Abstract]	'	'	'	'
Basic shares	56,356,885	55,908,574	56,216,200	55,826,306
Effect of dilutive securities:	'	'	'	'
Stock options	'	202,324	'	187,235
Diluted shares	56,356,885	56,110,898	56,216,200	56,013,541

Net_Loss_Income_Per_Common_Sha3

Net (Loss) Income Per Common Share - Additional Information (Detail)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Dilutive Securities Included And Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Options to purchase shares of common stock included in the computation of diluted EPS	'	202,324	'	187,235
Stock Options [Member]	'	'	'	'
Dilutive Securities Included And Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Options to purchase shares of common stock included in the computation of diluted EPS	'	202,324	'	187,235
Common Stock [Member]	'	'	'	'
Dilutive Securities Included And Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Anti-dilutive stock excluded from the computation of diluted EPS	262,695	'	276,164	'
Issued Stock Options [Member]	'	'	'	'
Dilutive Securities Included And Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Anti-dilutive stock excluded from the computation of diluted EPS	4,019,882	3,912,000	4,004,972	4,247,000
Series A Preferred Stock [Member]	'	'	'	'
Dilutive Securities Included And Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Anti-dilutive stock excluded from the computation of diluted EPS	50,000	'	50,000	'

Inventories_Components_of_Inve

Inventories - Components of Inventories (Detail) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Inventory Disclosure [Abstract]	'	'
Unprocessed tissue and raw materials	$31,775	$25,962
Tissue and work in process	39,839	28,379
Implantable tissue and finished goods	39,493	20,071
Supplies	2,031	2,097
Inventory - net	$113,138	$76,509

Inventories_Additional_Informa

Inventories - Additional Information (Detail) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Inventory Disclosure [Abstract]	'	'	'	'
Inventory write-downs	$552	$617	$1,898	$3,100

Property_Plant_and_Equipment_C

Property, Plant and Equipment - Components of Property, Plant and Equipment (Detail) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Property, Plant and Equipment [Line Items]	'	'
Land	$2,596	$2,169
Buildings and improvements	49,332	45,220
Processing equipment	42,665	31,681
Surgical instruments	4,527	'
Office equipment, furniture and fixtures	3,836	2,831
Computer equipment and software	6,152	5,029
Construction in process	13,650	7,329
Property, plant and equipment, gross	124,050	95,399
Less accumulated depreciation	-51,232	-45,755
Total	72,818	49,644
Processing Equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Equipment under capital leases	396	396
Computer Equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Equipment under capital leases	$896	$744

Property_Plant_and_Equipment_A

Property, Plant and Equipment - Additional Information (Detail) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Depreciation [Abstract]	'	'	'	'
Depreciation expense of property, plant and equipment	$2,644	$1,528	$5,716	$4,395

Goodwill_Goodwill_Detail

Goodwill - Goodwill (Detail) (USD $)	9 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Dec. 31, 2012	Jul. 16, 2013
Goodwill And Intangible Assets Disclosure [Abstract]	'	'	'
Beginning Balance, Goodwill	$2,062	'	$53,215
Goodwill acquired during the period	53,215	2,062	'
Ending Balance, Goodwill	$55,277	$2,062	$53,215

Other_Intangible_Assets_Compon

Other Intangible Assets - Components of Other Intangible Assets (Detail) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Finite-Lived Intangible Assets [Line Items]	'	'
Gross Carrying Amount	$46,745	$22,630
Accumulated Amortization	11,301	8,864
Patents [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Gross Carrying Amount	10,163	4,616
Accumulated Amortization	1,749	1,443
Acquired Exclusivity Rights [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Gross Carrying Amount	2,941	2,941
Accumulated Amortization	2,694	2,415
Acquired Licensing Rights [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Gross Carrying Amount	10,850	10,850
Accumulated Amortization	5,023	4,115
Marketing and Procurement Intangible Assets [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Gross Carrying Amount	22,791	4,223
Accumulated Amortization	$1,835	$891

Other_Intangible_Assets_Additi

Other Intangible Assets - Additional Information (Detail) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Goodwill And Intangible Assets Disclosure [Abstract]	'	'	'	'
Amortization expense of other intangible assets	$1,447	$507	$2,498	$1,519

Other_Intangible_Assets_Estima

Other Intangible Assets - Estimates of Future Amortization Expense (Detail) (USD $)	Sep. 30, 2013
In Thousands, unless otherwise specified
Goodwill And Intangible Assets Disclosure [Abstract]	'
2013	$1,500
2014	4,400
2015	4,100
2016	3,600
2017	3,600
Total future amortization expense	$17,200

Other_Assets_Schedule_of_Other

Other Assets - Schedule of Other Assets (Detail) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]	'	'
Indemnification asset	$13,000	'
Other	1,276	713
Total other assets	$14,276	$713

Other_Assets_Additional_Inform

Other Assets - Additional Information (Detail) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]	'	'	'	'
Indemnification asset	$13,000	'	$13,000	'
Deposited in escrow account	13,000	'	13,000	'
Indemnification liability	13,000	'	13,000	'
Interest expense associated with the amortization of debt issuance costs	$36	$42	$4	$20

Accrued_Expenses_Accrued_Expen

Accrued Expenses - Accrued Expenses (Detail) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Payables And Accruals [Abstract]	'	'
Accrued compensation	$6,703	$6,279
Accrued donor recovery fees	5,489	3,845
Accrued taxes	111	3,950
Contingent consideration	139	900
Other	7,121	5,620
Total accrued expenses	$19,563	$20,594

Short_and_LongTerm_Obligations2

Short and Long-Term Obligations - Short and Long-Term Obligations (Detail) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Debt Disclosure [Abstract]	'	'
Term loan	$60,000	'
Credit facilities	8,250	'
Capital leases	160	120
Total	68,410	120
Less current portion	-28	-116
Long-term portion	$68,382	$4

Short_and_LongTerm_Obligations3

Short and Long-Term Obligations - Additional Information (Detail)

9 Months Ended

9 Months Ended

1 Months Ended

9 Months Ended

1 Months Ended

1 Months Ended

In Thousands, unless otherwise specified

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Jul. 16, 2013

Sep. 30, 2013

Jul. 16, 2013

Jul. 16, 2013

Jul. 16, 2013

Jul. 16, 2013

Jul. 16, 2013

USD ($)

USD ($)

Credit Facilities [Member]

Capital Leases [Member]

German Banks [Member]

German Banks [Member]

German Banks [Member]

German Banks [Member]

German Banks [Member]

TD Bank and Regions Bank [Member]

TD Bank and Regions Bank [Member]

TD Bank and Regions Bank [Member]

TD Bank and Regions Bank [Member]

TD Bank and Regions Bank [Member]

TD Bank and Regions Bank [Member]

TD Bank and Regions Bank [Member]

Debt_Instruments

USD ($)

USD ($)

EUR (€)

Credit Facilities [Member]

Secured by Mortgage [Member]

Secured by Accounts Receivable [Member]

USD ($)

USD ($)

Senior Secured Facility [Member]

Bank Term Loan [Member]

Revolving Credit Facility [Member]

Minimum [Member]

Maximum [Member]

Debt_Instruments

EUR (€)

EUR (€)

USD ($)

USD ($)

Senior Secured Facility [Member]

Senior Secured Facility [Member]

Standby Letters of Credit [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Term of senior secured credit facility

'

'

'

'

'

'

'

'

'

'

'

'5 years

'

'

'

'

Amount of senior secured facility obtained

'

'

'

'

'

'

'

'

'

$80,000

'

'

$60,000

$20,000

'

'

Maturity date of senior secured credit facility

'

'

'

'

'

'

'

'

'

'

'

16-Jul-18

'

'

'

'

Variable interest rate, basis point

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1.00%

1.75%

Existing credit facility amount replaced by new revolving credit facility

'

'

'

'

'

'

'

'

'

'

15,000

'

'

'

'

'

Variable interest rate base

'

'

'

'

'

'

'

'

'

'One month LIBOR rate

'

'

'

'

'

'

Revolving credit facility variable interest rate

'

'

'

'

'

'

'

'

'

'

1.68%

'

'

'

'

'

Minimum cash balance required for covenant compliance

'

'

'

'

'

'

'

'

'

'

10,000

'

'

'

'

'

Covenant Terms of Credit Facility

'

'

'

'

'

'

'

'

'

'

'The new credit agreement also contains various restrictive covenants which limit, among other things, indebtedness and liens, require a minimum cash balance on hand of $10,000, and require certain financial covenant ratios.

'

'

'

'

'

Long-term obligations outstanding, number

'

'

4

'

'

'

3

'

'

'

'

'

'

'

'

'

Credit facility, current borrowing capacity

14,049

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Credit outstanding

8,250

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Credit facility, borrowing capacity

'

'

'

'

2,299

1,700

'

'

'

'

'

'

'

'

'

'

Credit facility, secured

'

'

'

'

'

'

'

1,000

500

'

'

'

'

'

'

'

Credit facility, unsecured amount

'

'

'

'

'

200

'

'

'

'

'

'

'

'

'

'

Minimum interest rates

'

'

'

1.49%

3.30%

3.30%

'

'

'

'

'

'

'

'

'

'

Maximum interest rates

'

'

'

8.46%

6.00%

6.00%

'

'

'

'

'

'

'

'

'

'

Capital leases maturity date

'2017

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Future maturities of capital leases

68,410

'

'

160

'

'

'

'

'

'

'

'

'

'

'

'

Interest included in minimum lease payments

8

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Present value of minimum lease payments

$152

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Short_and_Long_Term_Obligation

Short and Long - Term Obligations - Contractual Maturities of Long-Term Obligations (Detail) (USD $)	Sep. 30, 2013
In Thousands, unless otherwise specified
Schedule Of Short Term And Long Term Debt [Line Items]	'
2013	$20
2014	683
2015	5,294
2016	4,532
2017 and beyond	57,881
Capital leases, total	68,410
Term Loan [Member]	'
Schedule Of Short Term And Long Term Debt [Line Items]	'
2013	'
2014	625
2015	5,250
2016	4,500
2017 and beyond	49,625
Capital leases, total	60,000
Credit Facilities [Member]	'
Schedule Of Short Term And Long Term Debt [Line Items]	'
2013	'
2014	'
2015	'
2016	'
2017 and beyond	8,250
Capital leases, total	8,250
Capital Leases [Member]	'
Schedule Of Short Term And Long Term Debt [Line Items]	'
2013	20
2014	58
2015	44
2016	32
2017 and beyond	6
Capital leases, total	$160

Other_LongTerm_Liabilities_Sch

Other Long-Term Liabilities - Schedule of Other Long-Term Liabilities (Detail) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Other Liabilities Disclosure [Abstract]	'	'
Indemnification liability	$13,000	'
Other	1,626	698
Total other long-term liabilities	$14,626	$698

Other_LongTerm_Liabilities_Add

Other Long-Term Liabilities - Additional Information (Detail) (USD $)	Sep. 30, 2013
In Thousands, unless otherwise specified
Other Liabilities Disclosure [Abstract]	'
Indemnification liability	$13,000

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Detail) (USD $)	Sep. 30, 2013	Dec. 31, 2012	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2013
In Thousands, unless otherwise specified			Domestic Tax Authority [Member]	Range One [Member]	Range Two [Member]	Minimum [Member]	Maximum [Member]
				State [Member]	State [Member]	Foreign Tax Authority [Member]	Foreign Tax Authority [Member]
Operating Loss Carryforwards [Line Items]	'	'	'	'	'	'	'
Deferred tax assets	$24,952	'	'	'	'	'	'
Domestic deferred tax assets, net of valuation allowances	469	469	'	'	'	'	'
Net operating loss carryforwards	12,467	'	'	'	'	'	'
State net operating loss carryforwards expiration period, minimum in years	'	'	'	'2018	'	'	'
State net operating loss carryforwards expiration period, maximum in years	'	'	'	'	'2022 through 2024	'	'
Undistributed earrings of foreign subsidiaries	$8,486	$10,364	'	'	'	'	'
Periods of examination covering the subsidiaries	'	'	'2010	'	'	'2006	'2009

Preferred_Stock_Schedule_of_Pr

Preferred Stock - Schedule of Preferred Stock (Detail) (USD $)	9 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Dec. 31, 2012
Summary Activity In Gold Bullion [Line Items]	'	'
Preferred shares issuance	$49,381	'
Preferred shares issuance costs	-1,290	'
Net proceeds	48,710	'
Amortization of preferred shares issuance costs	46	'
Accrued dividend payable	625	'
Total	49,381	'
Series A Preferred Stock [Member]	'	'
Summary Activity In Gold Bullion [Line Items]	'	'
Preferred shares issuance	50,000	'
Amortization of preferred shares issuance costs	$46	'

Preferred_Stock_Additional_Inf

Preferred Stock - Additional Information (Detail) (USD $)	Sep. 30, 2013	Sep. 30, 2013	Dec. 31, 2012	Jul. 15, 2013	Jul. 15, 2013	Jun. 12, 2013	Jul. 15, 2013
In Thousands, except Per Share data, unless otherwise specified		Series A Preferred Stock [Member]	Series A Preferred Stock [Member]	Private Placement with WSHP [Member]	Private Placement with WSHP [Member]	Private Placement with WSHP [Member]	Maximum [Member]
				Series A Preferred Stock [Member]	Series A Preferred Stock [Member]	Series A Preferred Stock [Member]	Private Placement with WSHP [Member]
							Series A Preferred Stock [Member]
Summary Activity In Gold Bullion [Line Items]	'	'	'	'	'	'	'
Private placement of convertible preferred equity	$49,381	$50,000	'	'	'	$50,000	'
Convertible preferred stock, par value	$0.00	'	'	$0.00	$0.00	'	'
Preferred stock dividend rate	'	'	'	6.00%	'	'	12.00%
Preferred stock conversion price, per share	'	'	'	$4.39	$4.39	'	'
Convertible preferred stock number of shares to be issued for each share of preferred stock upon approval	'	'	'	$228	$228	'	'
Convertible preferred stock maximum number of shares to be issued percentage if approval not get	'	'	'	19.99%	19.99%	'	'
Closing price of share	'	'	'	$7.98	$7.98	'	'
Convertible preferred stock description of Conversion	'	'	'	'	'The Preferred Stock will be convertible at the election of the Company five years after its issuance or at any time if the Companybs common stock closes at or above $7.98 per share for at least 20 consecutive trading days	'	'
Preferred stock conversion after issuance, period	'	'	'	'	'5 years	'	'
Liquidation value	'	'	'	$1,000	$1,000	'	'
Convertible preferred stock description of Conversion Two	'	'	'	'	'The Company may, upon 30 days notice, redeem the Preferred Stock, in whole or in part, five years after its issuance at the liquidation value of $1,000 per share of the Preferred Stock plus an amount per share equal to accrued but unpaid dividends (collectively, the bLiquidation Valueb). The holders of the Preferred Stock may require the Company to redeem their Preferred Stock, in whole or in part, at the Liquidation Value seven years after its issuance or upon the occurrence of a change of control.	'	'
Preferred stock conversion after issuance, period Two	'	'	'	'	'7 years	'	'

Supplemental_Disclosures_of_Ca2

Supplemental Disclosures of Cash Flow and Noncash Investing and Financing Activities - Selected Cash Payments, Receipts, and Noncash Activities (Detail) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Additional Cash Flow Elements And Supplemental Cash Flow Information [Abstract]	'	'	'	'
Cash paid for interest	$246	$6	$249	$19
Income taxes paid	286	288	3,840	2,659
Change in tax benefit from stock-based compensation	120	410	120	197
Change in accrual for purchases of property, plant and equipment	2,035	74	2,835	188
Change in accrual for acquired intangible asset costs	808	1,275	668	1,439
Accrued dividend payable	$625	'	$625	'

Segment_Data_Additional_Inform

Segment Data - Additional Information (Detail)	9 Months Ended
	Sep. 30, 2013
	Segment
Segment Reporting [Abstract]	'
Number of reportable segments	1
Number of business lines	6

Segment_Data_Revenues_from_Tis

Segment Data - Revenues from Tissue Distribution and Other Revenues (Detail) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Segment Reporting Information [Line Items]	'	'	'	'
Other revenues	$1,521	$1,532	$6,355	$4,640
Total revenues	54,742	44,566	137,473	133,506
Domestic [Member]	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Revenues	49,295	39,643	122,822	116,707
International [Member]	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Revenues	5,447	4,923	14,651	16,799
Spine [Member] | Tissue Distribution [Member]	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Tissue distribution	17,600	10,187	38,920	28,532
Sports Medicine [Member] | Tissue Distribution [Member]	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Tissue distribution	9,532	11,811	31,700	38,573
Surgical Specialties [Member] | Tissue Distribution [Member]	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Tissue distribution	6,730	7,880	20,559	24,136
BGS and General Orthopedic [Member] | Tissue Distribution [Member]	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Tissue distribution	7,692	7,916	19,093	21,947
Dental [Member] | Tissue Distribution [Member]	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Tissue distribution	4,963	5,240	14,142	15,678
Ortho Fixation [Member] | Tissue Distribution [Member]	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Tissue distribution	$6,704	'	$6,704	'

Segment_Data_Schedule_of_Perce

Segment Data - Schedule of Percentage of Total Revenues Derived from Company's Largest Distributors and International Distribution (Detail) (Operating Segments [Member], Sales [Member])	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Medtronic, Inc.[Member]	'	'	'	'
Entity Wide Portfolio Carrying Amount, Major Customer [Line Items]	'	'	'	'
Percentage of sales revenue from international distribution	14.00%	19.00%	17.00%	18.00%
Zimmer, Inc.[Member]	'	'	'	'
Entity Wide Portfolio Carrying Amount, Major Customer [Line Items]	'	'	'	'
Percentage of sales revenue from international distribution	19.00%	15.00%	17.00%	14.00%
Davol , Inc.[Member]	'	'	'	'
Entity Wide Portfolio Carrying Amount, Major Customer [Line Items]	'	'	'	'
Percentage of sales revenue from international distribution	8.00%	12.00%	10.00%	12.00%
International Customers [Member]	'	'	'	'
Entity Wide Portfolio Carrying Amount, Major Customer [Line Items]	'	'	'	'
Percentage of sales revenue from international distribution	10.00%	11.00%	11.00%	13.00%

Segment_Data_Schedule_of_Prope

Segment Data - Schedule of Property, Plant and Equipment - Net by Significant Geographic Location (Detail) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'
Property, plant and equipment-net	$72,818	$49,644
Domestic [Member] | Operating Segments [Member]	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'
Property, plant and equipment-net	56,984	34,637
International [Member] | Operating Segments [Member]	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'
Property, plant and equipment-net	$15,834	$15,007

Commitments_and_Contingencies_1

Commitments and Contingencies - Additional Information (Detail) (USD $)

1 Months Ended

3 Months Ended

6 Months Ended

9 Months Ended

1 Months Ended

9 Months Ended

1 Months Ended

3 Months Ended

In Thousands, unless otherwise specified

Jul. 25, 2013

Dec. 28, 2012

14-May-07

Sep. 30, 2013

Mar. 31, 2013

Sep. 30, 2012

Jun. 30, 2013

Sep. 30, 2013

Sep. 30, 2012

Jul. 16, 2013

Sep. 30, 2010

14-May-07

Sep. 30, 2013

Sep. 10, 2010

Jul. 13, 2009

Mar. 31, 2013

Dec. 31, 2010

Lawsuits

Lawsuits

Lawsuits

Lawsuits

Zimmer, Inc.[Member]

Zimmer, Inc.[Member]

Zimmer, Inc.[Member]

Athersys, Inc. [Member]

Davol , Inc.[Member]

Davol , Inc.[Member]

Davol , Inc.[Member]

Commitment And Contingencies [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Maximum purchase price under agreement

'

$3,900

'

'

'

'

'

'

'

$126,307

'

'

'

'

'

'

'

Purchase price consideration, closing payment

'

3,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Additional services provided in connection with the assignment

'

900

'

761

'

'

'

761

'

'

'

'

'

'

'

'

'

Contingent payment is recorded in accrued expenses

'

'30 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Agreement initial term years

'

'

'

'

'

'

'

'

'

'

'10 years

'

'

'

'

'

'

Upfront payment

2,700

'

'

'

'

'

'

'

'

'

13,000

'

'

'

'

'

'

Upfront payment period

'

'

'

'

'

'

'

'

'

'

'10 days

'

'

'

'

'

'

Non-refundable license fee

'

'

'

'

'

'

'

'

'

'

'

'

'

3,000

8,000

'

'

License fee payable in three time-based installments

'

'

'

'

'

'

'

'

'

'

'

'

'

1,000

'

'

'

Payment contingent upon successful achievement of certain development milestones

'

'

'

'

'

'

'

'

'

'

'

'

'

2,000

'

'

'

Payment contingent upon achievement of certain cumulative revenue milestones

'

'

'

'

'

'

'

'

'

'

'

'

'

32,500

'

'

'

Exclusive license agreement period maximum

'

'

'

'

'

'

'

'

'

'

'

'

'

'5 years

'

'

'

Revenue milestone payment

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,500

Exclusivity payments

'

'

'

'

3,500

'

'

'

'

'

'

5,000

'

'

'

8,000

'

Exclusive worldwide distribution agreement extended expiration date

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

13-Jul-19

'

Additional deferred revenue

'

'

'

-1,182

'

-1,163

'

-5,229

-3,491

'

'

'

'

'

'

1,715

'

Distribution agreement automatic renewal terms

'

'

'

'

'

'

'

'

'

'

'

'

'2 years

'

'

'

'

Distribution Agreement Initial Term with Zimmer

'

'

'10 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Outstanding claims

'

'

'

0

'

'

'

0

'

'

'

'

'

'

'

'

'

Number of lawsuits settled by agreement on financial terms

'

'

'

'

'

29

'

'

29

'

'

'

'

'

'

'

'

Litigation settlement charges

'

'

'

'

'

'

3,000

'

2,350

'

'

'

'

'

'

'

'

Answerable indemnity insurance

'

'

'

2,000

'

'

'

2,000

'

'

'

'

'

'

'

'

'

Litigation contingent interest

$300

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Commitments_and_Contingencies_2

Commitments and Contingencies - Aggregate Future Minimum Lease Payments Under all Non-Cancellable Lease Agreements (Detail) (USD $)	Sep. 30, 2013
In Thousands, unless otherwise specified
Commitments And Contingencies Disclosure [Abstract]	'
2013	$559
2014	1,685
2015	739
2016	248
2017 and beyond	148
Total	$3,379

Related_Parties_Additional_Inf

Related Parties - Additional Information (Detail) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012
Related Party Transactions [Abstract]	'	'	'	'	'
Revenue from related parties	$651	$1,652	$2,087	$4,676	'
Percentage of company's total revenues	1.20%	3.70%	1.50%	3.50%	'
Trade accounts receivable due from Stryker	402	'	402	'	552
Trade accounts payable due to Stryker	$94	'	$94	'	$18

Subsequent_Events_Additional_I

Subsequent Events - Additional Information (Detail) (Subsequent Event [Member])	1 Months Ended
	Nov. 07, 2013
Subsequent Event [Line Items]	'
Basis of conversion of Series A Convertible Preferred Stock to common stock	'Series A Convertible Preferred Stock in excess of 19.99% of the common stock outstanding prior to such issuance
Series A Preferred Stock [Member]	'
Subsequent Event [Line Items]	'
Convertible preferred stock dividend rate	6.00%
Distribution Agreement with Medtronic [Member]	'
Subsequent Event [Line Items]	'
Agreement renewal term	'5 years
Distribution Agreement Initial Expiration Date	31-Dec-17